We are live on ! Find out more
KNSA icon

Kiniksa Pharmaceuticals
KNSA

62 hedge funds and large institutions have $167M invested in Kiniksa Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 25 increasing their positions, 11 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

127% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 11

80% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 10

26% more capital invested

Capital invested by funds: $132M → $167M (+$34.9M)

15% more funds holding

Funds holding: 54 → 62 (+8)

2.3% less ownership

Funds ownership: 81.05% → 78.75% (-2.3%)

Holders
62
Holders Change
+8
Holders Change %
+14.81%
% of All Funds
1.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
18
Increased
25
Reduced
11
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Ameriprise
Ameriprise
Minnesota
+$4.15M
2
GTC
Ghost Tree Capital
New York
+$3.04M
3
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
+$2.69M
4
ACH
ArrowMark Colorado Holdings
Colorado
+$2.07M
5
Millennium Management
Millennium Management
New York
+$1.82M

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$10.8M
2
VMI
VHCP Management II
New York
-$4.6M
3
VMI
VHCP Management III
New York
-$2.36M
4
Victory Capital Management
Victory Capital Management
Texas
-$2.02M
5
BlackRock
BlackRock
New York
-$1.47M
Name Holding Trade Value Shares
Change 		Change in
Stake
Deutsche Bank
51
Deutsche Bank
Germany
$54K +$9.74K +1,121 +29%
JP Morgan Chase
52
JP Morgan Chase
New York
$51K +$61 +7 +0.2%
Legal & General Group
53
Legal & General Group
United Kingdom
$34K +$4.67K +537 +21%
Citigroup
54
Citigroup
New York
$31K +$14.1K +1,623 +138%
BNP Paribas Financial Markets
55
BNP Paribas Financial Markets
France
$24.8K +$226 +26 +1%
Bank of Montreal
56
Bank of Montreal
Ontario, Canada
$20K +$4.77K +549 +45%
Royal Bank of Canada
57
Royal Bank of Canada
Ontario, Canada
$13K +$10.4K +1,196 New
AIP
58
Ameritas Investment Partners
Nebraska
$11K – – –
PHK
59
Point72 Hong Kong
Hong Kong
$3K -$478 -55 -16%
Carson Wealth (CWM LLC)
60
Carson Wealth (CWM LLC)
Nebraska
$1K – – –
DM
61
Deerfield Management
New York
– -$10.8M -1,274,086 Closed
VMI
62
VHCP Management II
New York
– -$4.6M -540,461 Closed
VMI
63
VHCP Management III
New York
– -$2.36M -277,137 Closed
Victory Capital Management
64
Victory Capital Management
Texas
– -$2.02M -236,905 Closed
Point72 Asset Management
65
Point72 Asset Management
Connecticut
– -$1.19M -140,000 Closed
AA
66
ALPS Advisors
Colorado
– -$325K -38,173 Closed
Swiss National Bank
67
Swiss National Bank
Switzerland
– -$166K -19,500 Closed
HSBC Holdings
68
HSBC Holdings
United Kingdom
– -$125K -14,730 Closed
Manulife (Manufacturers Life Insurance)
69
Manulife (Manufacturers Life Insurance)
Ontario, Canada
– -$92K -10,514 Closed
Daiwa Securities Group
70
Daiwa Securities Group
Japan
– -$1K -117 Closed
EI
71
Ellevest Inc
New York
– +$156 +18 New
OSAM
72
O'Shaughnessy Asset Management
Connecticut
– +$165 +19 New
1 2
3

KNSA Hedge Fund Activity: Q4 2019 in Review

62 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Kiniksa Pharmaceuticals (KNSA) for Q4 2019, worth a combined $167M — up 26% from $132M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new KNSA positions and 10 closed out — a net gain of 8 holders — while 25 added to existing stakes and 11 trimmed.

The largest buyer was Ameriprise, adding an estimated $4.15M. The largest seller was Deerfield Management, exiting entirely with an estimated $10.8M sold.

  • 62 institutional investors held Kiniksa Pharmaceuticals (KNSA) as of Q4 2019, up from 54 in Q3 2019.
  • Funds reported $167M of Kiniksa Pharmaceuticals stock for Q4 2019, up 26% quarter-over-quarter.
  • 18 funds opened new Kiniksa Pharmaceuticals positions in Q4 2019 and 10 closed out, a net change of +8 holders.
  • The largest Kiniksa Pharmaceuticals buyer in Q4 2019 was Ameriprise, an estimated $4.15M added.
  • The largest Kiniksa Pharmaceuticals seller in Q4 2019 was Deerfield Management, an estimated $10.8M sold.

Based on aggregated 13F filings for Q4 2019.